Proteinase 3 activity in sputum from subjects with alpha-1-antitrypsin deficiency and COPD

European Respiratory Journal

Volumn 41, Issue 5, 2013, Pages 1042-1050

  Sinden, Nicola J ^a   Stockley, Robert A ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Inflammatory mediators; Proteinases

Indexed keywords

ALPHA 1 ANTITRYPSIN; ELAFIN; LEUKOCYTE ELASTASE; MYELOBLASTIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ADULT; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME ACTIVITY; FEMALE; HUMAN; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TARGETING; SPUTUM EXAMINATION;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; INFLAMMATORY MEDIATORS; PROTEINASES;

AGED; ALPHA 1-ANTITRYPSIN DEFICIENCY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENOTYPE; HUMANS; INFLAMMATION; LEUKOCYTE ELASTASE; MALE; MIDDLE AGED; MYELOBLASTIN; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; REGISTRIES; SPUTUM;

EID: 84877099068     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00089712     Document Type: Article

References (48)

1. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004; 364: 613-620. (Pubitemid 39094180)
2. Abboud RT, Vimalanathan S. Pathogenesis of COPD. Part I. The role of protease-antiprotease imbalance in emphysema. Int J Tuberc Lung Dis 2008; 12: 361-367. (Pubitemid 351507246)
3. Laurell C-B, Eriksson S. The electrophoretic alpha 1 globulin pattern of serum in alpha 1 antitrypsin deficiency. Scand J Clin Lab Invest 1963; 15: 132-140.
4. Rao NV, Wehner NG, Marshall BC, et al. Characterization of proteinase-3 (PR-3), a neutrophil serine proteinase. Structural and functional properties. J Biol Chem 1991; 266: 9540-9548. (Pubitemid 21906690)
5. Doring G. The role of neutrophil elastase in chronic inflammation. Am J Respir Crit Care Med 1994; 150: S114-117. (Pubitemid 24364334)
6. Lucey EC, Stone PJ, Breuer R, et al. Effect of combined human neutrophil cathepsin G and elastase on induction of secretory cell metaplasia and emphysema in hamsters, with in vitro observations on elastolysis by these enzymes. Am Rev Respir Dis 1985; 132: 362-366. (Pubitemid 15229395)
7. Kao RC, Wehner NG, Skubitz KM, et al. Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters. J Clin Invest 1988; 82: 1963-1973. (Pubitemid 19054944)
8. Witko-Sarsat V, Halbwachs-Mecarelli L, Schuster A, et al. Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. Am J Respir Cell Mol Biol 1999; 20: 729-736. (Pubitemid 129495661)
9. Sallenave JM. Secretory leukocyte protease inhibitor and elafin/trappin-2: versatile mucosal antimicrobials and regulators of immunity. Am J Respir Cell Mol Biol 2010; 42: 635-643.
10. Travis J. Structure, function, and control of neutrophil proteinases. Am J Med 1988; 84: 37-42.
11. Ohbayashi H. Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs 2002; 11: 965-980. (Pubitemid 34732715)
12. Korkmaz B, Poutrain P, Hazouard E, et al. Competition between elastase and related proteases from human neutrophil for binding to alpha1-protease inhibitor. Am J Respir Cell Mol Biol 2005; 32: 553-559. (Pubitemid 40770134)
13. Baggiolini M, Bretz U, Dewald B, et al. The polymorphonuclear leukocyte. Agents Actions 1978; 8: 3-10. (Pubitemid 8274267)
14. Bories D, Raynal MC, Solomon DH, et al. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell 1989; 59: 959-968. (Pubitemid 20024607)
15. Campanelli D, Detmers PA, Nathan CF, et al. Azurocidin and a homologous serine protease from neutrophils. Differential anti-microbial and proteolytic properties. J Clin Invest 1990; 85: 904-915. (Pubitemid 20087495)
16. Campbell EJ, Campbell MA, Owen CA. Bioactive proteinase 3 on the cell surface of human neutrophils: quantification, catalytic activity, and susceptibility to inhibition. J Immunol 2000; 165: 3366-3374.
17. Coeshott C, Ohnemus C, Pilyavskaya A, et al. Converting enzyme-independent release of tumor necrosis factor α and IL-1β from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc Natl Acad Sci USA 1999; 96: 6261-6266. (Pubitemid 29256653)
18. Pendergraft WF 3rd, Rudolph EH, Falk RJ, et al. Proteinase 3 sidesteps caspases and cleaves p21(Waf1/Cip1/Sdi1) to induce endothelial cell apoptosis. Kidney Int 2004; 65: 75-84. (Pubitemid 38040086)
19. Fujinaga M, Chernaia MM, Halenbeck R, et al. The crystal structure of PR3, a neutrophil serine proteinase antigen of Wegener's granulomatosis antibodies. J Mol Biol 1996; 261: 267-278. (Pubitemid 26275808)
20. Korkmaz B, Attucci S, Moreau T, et al. Design and use of highly specific substrates of neutrophil elastase and proteinase 3. Am J Respir Cell Mol Biol 2004; 30: 801-807. (Pubitemid 38736903)
21. Korkmaz B, Attucci S, Juliano MA, et al. Measuring elastase, proteinase 3 and cathepsin G activities at the surface of human neutrophils with fluorescence resonance energy transfer substrates. Nat Protoc 2008; 3: 991-1000. (Pubitemid 351818687)
22. Sapey E, Bayley D, Ahmad A, et al. Inter-relationships between inflammatory markers in patients with stable COPD with bronchitis: intra-patient and inter-patient variability. Thorax 2008; 63: 493-499. (Pubitemid 351831157)
23. GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011. Available from: www.goldcopd.org/guidelines-global-strategy-for-diagnosis- management.html
24. Pye A, Stockley RA, Hill SL. Simple method for quantifying viable bacterial numbers in sputum. J Clin Pathol 1995; 48: 719-724.
25. Nakajima K, Powers JC, Ashe BM, et al. Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase. Studies with peptide substrates related to the alpha 1-protease inhibitor reactive site. J Biol Chem 1979; 254: 4027-4032. (Pubitemid 9178816)
26. Korkmaz B, Hajjar E, Kalupov T, et al. Influence of charge distribution at the active site surface on the substrate specificity of human neutrophil protease 3 and elastase. A kinetic and molecular modeling analysis. J Biol Chem 2007; 282: 1989-1997. (Pubitemid 47076700)
27. Wiesner O, Litwiller RD, Hummel AM, et al. Differences between human proteinase 3 and neutrophil elastase and their murine homologues are relevant for murine model experiments. FEBS Lett 2005; 579: 5305-5312. (Pubitemid 41395148)
28. Llewellyn-Jones CG, Harris TA, Stockley RA. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med 1996; 153: 616-621. (Pubitemid 26051337)
29. Kessler E, Israel M, Landshman N, et al. In vitro inhibition of Pseudomonas aeruginosa elastase by metal-chelating peptide derivatives. Infect Immun 1982; 38: 716-723. (Pubitemid 12002695)
30. Ying QL, Simon SR. Elastolysis by proteinase 3 and its inhibition by alpha(1)-proteinase inhibitor: a mechanism for the incomplete inhibition of ongoing elastolysis. Am J Respir Cell Mol Biol 2002; 26: 356-361. (Pubitemid 34170062)
31. Rao NV, Marshall BC, Gray BH, et al. Interaction of secretory leukocyte protease inhibitor with proteinase-3. Am J Respir Cell Mol Biol 1993; 8: 612-616.
32. White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease. 6: the aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 2003; 58: 73-80. (Pubitemid 36135363)
33. Brusse-Keizer M, van der Palen J, van der Valk P, et al. Clinical predictors of exacerbation frequency in chronic obstructive pulmonary disease. Clin Respir J 2011; 5: 227-234.
34. Snoeck-Stroband JB, Postma DS, Lapperre TS, et al. Airway inflammation contributes to health status in COPD: a cross-sectional study. Respir Res 2006; 7: 140.
35. Gompertz S, Hill AT, Bayley DL, et al. Effect of expectoration on inflammation in induced sputum in alpha-1-antitrypsin deficiency. Respir Med 2006; 100: 1094-1099.
36. Lee RL, Rancourt RC, del Val G, et al. Thioredoxin and dihydrolipoic acid inhibit elastase activity in cystic fibrosis sputum. Am J Physiol Lung Cell Mol Physiol 2005; 289: L875-L882. (Pubitemid 41504420)
37. Simpson JL, Scott RJ, Boyle MJ, et al. Differential proteolytic enzyme activity in eosinophilic and neutrophilic asthma. Am J Respir Crit Care Med 2005; 172: 559-565. (Pubitemid 41232966)
38. Hill AT, Campbell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000; 109: 288-295.
39. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153: 1530-1535. (Pubitemid 26141336)
40. Zedtwitz-Liebenstein K, Schenk P, Apfalter P, et al. Ventilator- associated pneumonia: increased bacterial counts in bronchoalveolar lavage by using urea as an endogenous marker of dilution. Crit Care Med 2005; 33: 756-759.
41. Stone H, McNab G, Wood AM, et al. Variability of sputum inflammatory mediators in COPD and alpha-1-antitrypsin deficiency. Eur Respir J 2012; 40: 561-569.
42. Weldon S, McNally P, McElvaney NG, et al. Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation. J Immunol 2009; 183: 8148-8156.
43. Guyot N, Butler MW, McNally P, et al. Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis. J Biol Chem 2008; 283: 32377-32385.
44. Marin A, Garcia-Aymerich J, Sauleda J, et al. Effect of bronchial colonisation on airway and systemic inflammation in stable COPD. COPD 2012; 9: 121-130.
45. Churg A, Zhou S, Wright JL. Matrix metalloproteinases in COPD. Eur Respir J 2012; 39: 197-209.
46. Mason RW, Johnson DA, Barrett AJ, et al. Elastinolytic activity of human cathepsin L. Biochem J 1986; 233: 925-927. (Pubitemid 16116171)
47. Lesser M, Padilla ML, Cardozo C. Induction of emphysema in hamsters by intratracheal instillation of cathepsin B. Am Rev Respir Dis 1992; 145: 661-668.
48. Jegot G, Derache C, Castella S, et al. A substrate-based approach to convert SerpinB1 into a specific inhibitor of proteinase 3, the Wegener's granulomatosis autoantigen. FASEB J 2011; 25: 3019-3031.